In our AOM/DSS‐induced model, the group treated with anti‐PD1 antibody showed a slight decrease in tumor frequency and size without statistical significance, similar to the results of a previous study.[35] However, surprisingly, the frequency and size of tumors was significantly reduced in the groups treated with anti‐CXCL12 antibody, regardless of anti‐PD1 antibody treatment (Figure 7C,D). This evidence concerns the gene CXCL12 and infectious otitis media.